Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

• Published in: Leukemia 2020-12, Vol.34 (12), p.3338-3347
• Main Authors: Dhakal, Binod, Patel, Sagar, Girnius, Saulius, Bachegowda, Lohith, Fraser, Raphael, Davila, Omar, Kanate, Abraham S., Assal, Amer, Hanbali, Amr, Bashey, Asad, Pawarode, Attaphol, Freytes, César O., Lee, Cindy, Vesole, David, Cornell, Robert Frank, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Yared, Jean A., Schriber, Jeffrey, Berdeja, Jesus, Stockerl-Goldstein, Keith, Meehan, Kenneth, Holmberg, Leona, Solh, Melhem, Diaz, Miguel Angel, Kharfan-Dabaja, Mohamed A., Farhadfar, Nosha, Bashir, Qaiser, Munker, Reinhold, Olsson, Richard F., Gale, Robert P., Bayer, Ruthlee-Lu, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Badawy, Sherif M., Nishihori, Taiga, Gonsalves, Wilson, Nieto, Yago, Efebera, Yvonne, Kumar, Shaji, Shah, Nina, Qazilbash, Muzaffar, Hari, Parameswaran, D’Souza, Anita
• Format: Article
• Language: English
• Subjects: 692/308/2171; 692/699/67; Adult; Aged; Autografts; Cancer; Cancer Research; Care and treatment; Cohort Studies; Critical Care Medicine; Development and progression; Female; Graft vs Host Disease - etiology; Hematology; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic stem cells; Humans; Intensive; Internal Medicine; Leukemia; Leukemia, Plasma Cell - surgery; Leukemia, Plasma Cell - therapy; Longitudinal Studies; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Oncology, Experimental; Plasma cell leukemia; Progression-Free Survival; Recurrence; Stem cell transplantation; Survival; Transplantation; Transplantation Conditioning - methods; Transplantation, Autologous - methods; Transplantation, Homologous - methods
• ISSN: 0887-6924; 1476-5551; 1476-5551
• DOI: 10.1038/s41375-020-0830-0

The outcomes of patients with primary plasma cell leukemia (pPCL) after undergoing hematopoietic cell transplantation (HCT) in the novel agent era are unknown. We report outcomes of 348 patients with pPCL receiving autologous (auto-) HCT ( n  = 277) and allogeneic (allo-) HCT ( n  = 71) between 2008 and 2015. Median age was 60 years and 56 years for auto- and allo-HCT respectively. For auto-HCT, the 4-year outcomes were: non-relapse mortality (NRM) 7% (4–11%), relapse (REL) 76% (69–82%), progression-free survival (PFS) 17% (13–23%), and overall survival (OS) 28% (22–35%). Karnofsky performance status (KPS) > 90 and ≥very good partial response (VGPR) predicted superior OS in multi-variate analysis for auto-HCT. For allo-HCT, the 4-year outcomes were: NRM 12% (5–21%), REL 69% (56–81%), PFS 19% (10–31%), and OS 31% (19–44%). Compared with prior CIBMTR pPCL patients (1995–2006), inferior survival was noted in the current cohort (3-year OS, 39% vs. 38% in allo-HCT, and 62% vs. 35% in auto-HCT) respectively. However, we noted an increased HCT utilization, from 12% (7–21%) in 1995 to 46% (34–64%) in 2009 using SEER data (available till 2009). Despite modern induction translating to higher proportion receiving HCT, the outcomes remain poor in pPCL patients, mainly derived by high relapse rates post-HCT.